Penumbra (PEN) Stock Forecast & Price Target

Compare

428 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

PEN Analyst Ratings

Strong Buy

12 Buy

4 Hold

0 Sell

Based on 16 analysts giving stock ratings to

Penumbra

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

PEN Stock 12 Month Forecast

Average Price Target

$319.58

▲(26.16%Upside)

Based on 16 Wall Street analysts offering 12 month price targets for Penumbra in the last 3 months. The average price target is $319.58 with a high forecast of $340.00 and a low forecast of $260.00. The average price target represents a 26.16% change from the last price of $253.31.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"170":"$170","341":"$341","212.75":"$212.8","255.5":"$255.5","298.25":"$298.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":340,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$340.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":319.58,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$319.58</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":260,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$260.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[170,212.75,255.5,298.25,341],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,256.16,262.6092307692308,269.0584615384616,275.5076923076923,281.9569230769231,288.40615384615387,294.85538461538465,301.3046153846154,307.75384615384615,314.20307692307694,320.6523076923077,327.10153846153844,333.5507692307692,{"y":340,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,256.16,261.03846153846155,265.91692307692307,270.79538461538465,275.67384615384617,280.5523076923077,285.4307692307692,290.3092307692308,295.1876923076923,300.06615384615384,304.94461538461536,309.82307692307694,314.70153846153846,{"y":319.58,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,256.16,256.4553846153846,256.75076923076927,257.04615384615386,257.3415384615385,257.6369230769231,257.9323076923077,258.22769230769234,258.5230769230769,258.8184615384615,259.11384615384617,259.40923076923076,259.7046153846154,{"y":260,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":189.47,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":177.09,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":171.25,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":202.32,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":191.56,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":233.3,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":244.84,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":237.48,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":266.97,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":285.44,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":271.13,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":291.82,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":256.16,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$340.00

Average Price Target$319.58

Lowest Price Target$260.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$303

Buy

19.62%

Upside

Reiterated

05/16/25

Penumbra's overall stock score reflects strong financial performance with notable revenue and margin growth, primarily driven by its U.S. thrombectomy business. However, the high P/E ratio suggests potential overvaluation, and short-term technical indicators point to possible weakness. The earnings call provided positive growth insights but also highlighted challenges in international markets. These factors collectively contribute to a balanced overall score.

Travis SteedBank of America Securities

Bank of America Securities

$320

Buy

26.33%

Upside

Reiterated

06/09/25

Bank of America Securities Remains a Buy on Penumbra (PEN)

Margaret KaczorWilliam Blair

William Blair

―

Buy

―

Reiterated

06/04/25

Penumbra: Strong Market Position and Growth Potential Drive Buy Rating

Larry BiegelsenWells Fargo

Wells Fargo

$315

Buy

24.35%

Upside

Reiterated

05/29/25

Penumbra's Growth Potential Boosted by STORM-PE Trial and Thunderbolt Device Innovations

Rajan GuptaWilliam O'Neil

Not Ranked

William O'Neil

―

Hold

―

Downgraded

05/29/25

William ONeil downgrades Penumbra (PEN) to HoldWilliam ONeil analyst Raj Gupta downgraded Penumbra (NYSE: PEN) from Buy to Hold.

Joanne WuenschCiti

Citi

$320

Hold

26.33%

Upside

Reiterated

05/22/25

Penumbra (PEN) Gets a Hold from Citi

Matthew O'BrienPiper Sandler

Piper Sandler

$330

Buy

30.28%

Upside

Reiterated

05/09/25

Penumbra (PEN) Receives a Buy from Piper Sandler

Richard NewitterTruist Financial

Truist Financial

―

Buy

―

Reiterated

04/24/25

Analysts Conflicted on These Healthcare Names: Amedisys (NASDAQ: AMED), Siemens Healthineers AG (Other OTC: SEMHF) and Penumbra (NYSE: PEN)

Mike KratkyLeerink Partners

Leerink Partners

$313→$327

Buy

29.09%

Upside

Reiterated

04/24/25

Penumbra's Strong Growth Potential and Strategic U.S. Focus Earns 'Buy' Rating

Mathew BlackmanStifel Nicolaus

Stifel Nicolaus

$301→$318

Buy

25.54%

Upside

Reiterated

04/24/25

Penumbra price target raised to $318 from $301 at StifelPenumbra price target raised to $318 from $301 at Stifel

David RescottRobert W. Baird

Robert W. Baird

$316→$325

Buy

28.30%

Upside

Reiterated

04/24/25

Penumbra price target raised to $325 from $316 at BairdPenumbra price target raised to $325 from $316 at Baird

William PlovanicCanaccord Genuity

Canaccord Genuity

$340

Buy

34.22%

Upside

Reiterated

04/24/25

Penumbra's Strong Q1 Performance and Strategic Positioning Justify Buy Rating Despite Conservative FY25 Guidance

Kallum TitchmarshMorgan Stanley

Morgan Stanley

$260

Hold

2.64%

Upside

Reiterated

04/24/25

Analysts Offer Insights on Healthcare Companies: Astellas Pharma (Other OTC: ALPMF), Penumbra (NYSE: PEN) and Genmab (NASDAQ: GMAB)

Priya SachdevaUBS

UBS

$320→$330

Buy

30.28%

Upside

Reiterated

04/24/25

Penumbra price target raised to $330 from $320 at UBSPenumbra price target raised to $330 from $320 at UBS

Ryan ZimmermanBTIG

BTIG

$305→$320

Buy

26.33%

Upside

Reiterated

04/24/25

Penumbra price target raised to $320 from $305 at BTIGPenumbra price target raised to $320 from $305 at BTIG

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$303

Buy

19.62%

Upside

Reiterated

05/16/25

Travis SteedBank of America Securities

Bank of America Securities

$320

Buy

26.33%

Upside

Reiterated

06/09/25

Bank of America Securities Remains a Buy on Penumbra (PEN)

Margaret KaczorWilliam Blair

William Blair

―

Buy

―

Reiterated

06/04/25

Penumbra: Strong Market Position and Growth Potential Drive Buy Rating

Larry BiegelsenWells Fargo

Wells Fargo

$315

Buy

24.35%

Upside

Reiterated

05/29/25

Penumbra's Growth Potential Boosted by STORM-PE Trial and Thunderbolt Device Innovations

Rajan GuptaWilliam O'Neil

Not Ranked

William O'Neil

―

Hold

―

Downgraded

05/29/25

William ONeil downgrades Penumbra (PEN) to HoldWilliam ONeil analyst Raj Gupta downgraded Penumbra (NYSE: PEN) from Buy to Hold.

Joanne WuenschCiti

Citi

$320

Hold

26.33%

Upside

Reiterated

05/22/25

Penumbra (PEN) Gets a Hold from Citi

Matthew O'BrienPiper Sandler

Piper Sandler

$330

Buy

30.28%

Upside

Reiterated

05/09/25

Penumbra (PEN) Receives a Buy from Piper Sandler

Richard NewitterTruist Financial

Truist Financial

―

Buy

―

Reiterated

04/24/25

Analysts Conflicted on These Healthcare Names: Amedisys (NASDAQ: AMED), Siemens Healthineers AG (Other OTC: SEMHF) and Penumbra (NYSE: PEN)

Mike KratkyLeerink Partners

Leerink Partners

$313→$327

Buy

29.09%

Upside

Reiterated

04/24/25

Penumbra's Strong Growth Potential and Strategic U.S. Focus Earns 'Buy' Rating

Mathew BlackmanStifel Nicolaus

Stifel Nicolaus

$301→$318

Buy

25.54%

Upside

Reiterated

04/24/25

Penumbra price target raised to $318 from $301 at StifelPenumbra price target raised to $318 from $301 at Stifel

David RescottRobert W. Baird

Robert W. Baird

$316→$325

Buy

28.30%

Upside

Reiterated

04/24/25

Penumbra price target raised to $325 from $316 at BairdPenumbra price target raised to $325 from $316 at Baird

William PlovanicCanaccord Genuity

Canaccord Genuity

$340

Buy

34.22%

Upside

Reiterated

04/24/25

Penumbra's Strong Q1 Performance and Strategic Positioning Justify Buy Rating Despite Conservative FY25 Guidance

Kallum TitchmarshMorgan Stanley

Morgan Stanley

$260

Hold

2.64%

Upside

Reiterated

04/24/25

Analysts Offer Insights on Healthcare Companies: Astellas Pharma (Other OTC: ALPMF), Penumbra (NYSE: PEN) and Genmab (NASDAQ: GMAB)

Priya SachdevaUBS

UBS

$320→$330

Buy

30.28%

Upside

Reiterated

04/24/25

Penumbra price target raised to $330 from $320 at UBSPenumbra price target raised to $330 from $320 at UBS

Ryan ZimmermanBTIG

BTIG

$305→$320

Buy

26.33%

Upside

Reiterated

04/24/25

Penumbra price target raised to $320 from $305 at BTIGPenumbra price target raised to $320 from $305 at BTIG

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Penumbra

1 Month

xxx

Success Rate

14/20 ratings generated profit

Average Return

+6.64%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 70.00% of your transactions generating a profit, with an average return of +6.64% per trade.

3 Months

xxx

Success Rate

21/35 ratings generated profit

Average Return

+3.27%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +3.27% per trade.

1 Year

Richard NewitterTruist Financial

Success Rate

10/15 ratings generated profit

Average Return

+1.31%

reiterated a buy rating 2 months ago

Copying Richard Newitter's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +1.31% per trade.

2 Years

xxx

Success Rate

24/35 ratings generated profit

Average Return

+10.55%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 68.57% of your transactions generating a profit, with an average return of +10.55% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PEN Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, PEN has received 21 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. PEN average Analyst price target in the past 3 months is 319.58.

Each month's total comprises the sum of three months' worth of ratings.

PEN Financial Forecast

PEN Earnings Forecast

Next quarter’s earnings estimate for PEN is $0.82 with a range of $0.71 to $0.90. The previous quarter’s EPS was $0.83. PEN beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 49.75% of the time in the same period. In the last calendar year PEN has Outperformed its overall industry.

PEN Sales Forecast

Next quarter’s sales forecast for PEN is $327.75M with a range of $325.50M to $334.00M. The previous quarter’s sales results were $324.14M. PEN beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 50.54% of the time in the same period. In the last calendar year PEN has Outperformed its overall industry.

PEN Stock Forecast FAQ

What is PEN’s average 12-month price target, according to analysts?

Based on analyst ratings, Penumbra’s 12-month average price target is 319.58.

What is PEN’s upside potential, based on the analysts’ average price target?

Penumbra has 26.16% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is PEN a Buy, Sell or Hold?

Penumbra has a consensus rating of Strong Buy which is based on 12 buy ratings, 4 hold ratings and 0 sell ratings.

What is Penumbra’s price target?

The average price target for Penumbra is 319.58. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $340.00 ,the lowest forecast is $260.00. The average price target represents 26.16% Increase from the current price of $253.31.

What do analysts say about Penumbra?

Penumbra’s analyst rating consensus is a Strong Buy. This is based on the ratings of 16 Wall Streets Analysts.

How can I buy shares of PEN?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Penumbra (PEN) Stock Forecast & Price Target

PEN Analyst Ratings

PEN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Penumbra

PEN Analyst Recommendation Trends

PEN Financial Forecast

PEN Earnings Forecast

PEN Sales Forecast

PEN Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts